Mediwound ( (MDWD) ) has released its Q2 earnings. Here is a breakdown of the information Mediwound presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MediWound Ltd. is a global biotechnology company specializing in enzymatic therapies for non-surgical tissue repair, with products like NexoBrid® for burn treatment and EscharEx® for chronic wound debridement. In its second quarter of 2025, MediWound reported a revenue increase of 43% from the previous quarter, reaching $5.7 million, while continuing to advance its clinical trials and manufacturing capabilities. Key highlights include ongoing patient enrollment in the VALUE Phase III trial for EscharEx®, strategic partnerships with Essity and Convatec, and a six-fold expansion in NexoBrid® production capacity expected by the end of 2025. Despite a net loss of $13.3 million due to increased R&D and administrative expenses, the company remains committed to its long-term growth strategy. Looking forward, MediWound plans to leverage its expanded manufacturing capacity and strategic collaborations to meet anticipated demand and enhance its market presence.